

2025 Current Fiscal Year Report: National Cancer Advisory Board

Report Run Date: 07/04/2025 08:13:47 AM

1. Department or Agency

Department of Health and Human
Services

2. Fiscal Year

2025

3. Committee or Subcommittee

National Cancer Advisory Board

3b. GSA Committee

No.

960

4. Is this New During Fiscal Year?

5. Current Charter

6. Expected Renewal Date

7. Expected Term Date

No 05/31/2024 05/31/2026

8a. Was Terminated During Fiscal Year?

No

8b. Specific Termination Authority

8c. Actual Term Date

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority

Statutory (Congress Created)

12. Specific Establishment Authority

42 U.S.C. 284a

13. Effective Date

11/20/1985

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Other Committee

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a. Open

0

17b. Closed

1

17c. Partially Closed

1

Other Activities

0

17d. Total

2

Meetings and Dates

Purpose

Program Advisory

Program Advisory / Second Level Peer
Review

Start

12/02/2024 - 12/03/2024

End

06/10/2025 - 06/10/2025

Number of Committee Meetings Listed: 2

Current Next

FY FY

18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Administrative Costs (FRNs, contractor support, In-person/hybrid/virtual meetings)	\$0.00	\$0.00
18d. Other (all other funds not captured by any other cost category)	\$0.00	\$0.00
18e. Total Costs	\$0.00	\$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

The National Cancer Advisory Board (NCAB), composed of both scientific and public members, provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed \$50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). In FY 2024,

the NCAB reviewed 14,437 NCI applications requesting \$5,669,050,029 and 3 FDA SBIR applications requesting \$287,455. During the year, the NCAB was presented reports on various topics related to cancer research in general. Board discussions and reports included a wide variety of topics including CDK4/6 Activity During the Cell Cycle by Live-Cell Imaging; Integrative Population-Based Characterization of Mosaic Chromosomal Alterations Uncovering Etiologic Insights for Hematologic Malignancies; Complexity of Genomic Aberrations in Human Breast Cancer for Precision Oncology; NCI Center for Cancer Genomics; NCI Virtual Clinical Trials Office Pilot Program; NCI's Support of Early Career Cancer Investigators; NCI's Childhood Cancer Data Initiative (CCDI); Artificial Intelligence (AI); the NCI Community Oncology Research Program (NCORP); and the National Clinical Trials Network (NCTN). NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittees on Experimental Therapeutics and Population Sciences, Epidemiology, and Disparities. They also provided insights regarding reports from the NCAB Subcommittees on Planning and Budget; Cancer Centers; and Clinical Investigations. At the Joint Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism, National Advisory Council on Drug Abuse and NCAB met to hear reports regarding the Healthy Brain and Child Development (HBCD) Study; Adolescent Brain and Cognitive Development (ABCD) Study; the START Program and Advancing the Prediction of Adolescent Alcohol Use Onset by Deriving PolyExposure Alcohol Risk Scores using the ABCD Study; Racial Inequities and Neuroimaging Findings in ABCD; and updates from the NCI, NIAAA, and NIDA regarding efforts associated with the

Collaborative Research on Addiction at NIH (CRAN) initiative. Lastly, NCAB meeting minutes for the following meetings, i.e., the September 2023 virtual meeting, November 2023 Joint NCI Board of Scientific Advisors/NCAB virtual meeting, February 2024 virtual meeting, NIAAA/NIDA/NCAB May 2024 hybrid meeting, and June 2024 Joint NCI BSA/NCAB in-person/hybrid meeting were approved by the Board members during fiscal year 2024.

20b. How does the Committee balance its membership?

The Board will consist of not more than 18 members appointed by the President (appointed members) and 12 nonvoting ex officio members. The nonvoting ex officio members will include the Secretary; the Director of the Office of Science and Technology Policy; the Director, NIH; the Under Secretary for Health of the Department of Veterans Affairs; the Director of the National Institute for Occupational Safety and Health; the Director of the National Institute of Environmental Health Sciences; the Secretary of Labor; the Commissioner of the Food and Drug Administration; the Administrator of the Environmental Protection Agency; the Chairman of the Consumer Product Safety Commission; the Assistant Secretary of Defense for Health Affairs; and the Director of the Office of Energy Research of the Department of Energy (or their designees). All appointed members must be eligible to serve as Special Government Employees (SGEs) and will serve as SGEs. Two-thirds of the appointed members will be selected from among the leading representatives of the health and scientific disciplines (including not less than 2 individuals who are leaders in the fields of public health and the behavioral or social sciences) relevant to the

activities of NCI. One-third of the appointed members will be representatives from the general public, including leaders in fields of public policy, law, health policy, economics and management. Not less than five of the appointed members will be individuals knowledgeable in environmental carcinogenesis (including carcinogenesis involving occupational and dietary factors). Not less than one member shall be an individual knowledgeable in pediatric oncology.

20c. How frequent and relevant are the Committee Meetings?

As mandated, meetings are held not less than four times a year. The committee met five times during this reporting period. The Board met jointly with NIAAA/NIDA on 8 May 2024 hybrid and jointly with the NCI Board of Scientific Advisors for the November 2023 virtual and June 2024 in-person/hybrid meetings. The Board also met virtually at the February 2024 and in-person/hybrid at the September 2024 meetings. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing scientific programs. The Ad Hoc Subcommittee on Experimental Therapeutics and the Subcommittee on Cancer Centers met on 29 November 2023. The Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities, the Ad Hoc Subcommittee on Experimental Therapeutics, and the Subcommittee on Planning and Budget met on 8 February 2024. The Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities, the Ad Hoc Subcommittee on Experimental Therapeutics, and

the Subcommittee on Clinical Investigations met on 11 June 2024. The Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities, and the Ad Hoc Subcommittee on Experimental Therapeutics met on 3 September 2024.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The NCAB provides second level of peer review and advises on policy development; program implementation, and evaluation; and identifies research needs and opportunities of the Institute. The quality, scope, and balance of advice from this Board cannot be obtained from NIH staff or from other established sources as membership of the Board is constituted to meet specific requirements of the mandated mission of the Board and of the NCI.

20e. Why is it necessary to close and/or partially closed committee meetings?

The meetings of the NCAB were partially closed to the public for the review of grant applications. Sections 552b(c)(4) and 552b(c)(6) of the Government in the Sunshine Act permit the closing of meetings where discussion of applications could reveal confidential trade secrets or commercial property such as patentable material and personal information, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

21. Remarks

Committee Function: Other - National Scientific and Advisory. Max Number of Members Total: The Charter allows the Committee to have 30 authorized members included but not limited to 18 SGEs and 12 Ex-Officio Members. There are 8

Alternates to Ex-Officio Members (Drs. Joseph R. Graber, John Gordon, Michelle Heacock, Michael Kelley, Mathew Memoli, Richard Pazdur, Craig Shriver, and Kerry Souza), which is a total of 26 members, four less than the Max number of members. Members Rotating Off/On-Boarding: no member rotated-off and five members were on-boarded (Drs. Callisia Clarke, Karen Emmons, Ediah Nduom, Kimberly Stegmaier and Mrs. Tamika Felder). This is why the Charter states 18 potential members, and this ACR lists 18 current members. Members: Dr. Luis Diaz was terminated. As such, his term of service end date is different than what was reported on the FY24 ACR. Ex Officio Members: Dr. Joseph Graber has resigned. As such, his term of service end date is different than what was reported on the FY24 ACR. The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute. Reports: The NCAB did not produce a report this fiscal year.

Designated Federal Officer

PAULETTE S. GRAY DIRECTOR, DIVISION OF
EXTRAMURAL ACTIVITIES, NCI

Committee Members	Start	End	Occupation	Member Designation
ANDERSON, MARGARET	08/27/2023	03/09/2028	MANAGER DIRECTOR, DELOITTE CONSULTING LLP	Special Government Employee (SGE) Member
			PROFESSOR OF ONCOLOGY, CO-DIRECTOR, DEVELOPMENTAL THERAPEUTICS	Special Government
AZAD, NILOFER	01/30/2022	03/09/2026	PROGRAM, CO-LEADER, CANCER GENETICS AND EPIGENETICS SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER, JOHNS HOPKINS UNIVERSITY	Employee (SGE) Member

BOXER, RICHARD	08/27/2023	03/09/2028	CLINICAL PROFESSOR, DEPARTMENT OF UROLOGY, DAVID GEFEN SCHOOL OF MEDICINE, UNIVERSITY OF CALIFORNIA, LOS ANGELES	Special Government Employee (SGE) Member
CARPTEN, JOHN	12/05/2021	03/09/2026	DIRECTOR, COMPREHENSIVE CANCER CENTER, DIRECTOR AND CHIEF SCIENCE OFFICER, BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE	Special Government Employee (SGE) Member
CLARKE, CALLISIA	10/20/2024	03/09/2030	CHIEF, DIVISION OF SURGICAL ONCOLOGY, ASSOCIATE PROFESSOR OF SURGERY, DEPARTMENT OF SURGERY, MEDICAL COLLEGE OF WISCONSIN	Special Government Employee (SGE) Member
DIAZ, LUIS	07/31/2022	03/09/2025	HEAD, DIVISION OF SOLID TUMOR ONCOLOGY, GRAYER FAMILY CHAIR IN MEDICINE, DEPARTMENT OF MEDICINE, MEMORIAL SLOAN KETTERING CANCER CENTER	Special Government Employee (SGE) Member
DURON, YSABEL	08/27/2023	03/09/2028	FOUNDER AND EXECUTIVE DIRECTOR, THE LATINO CANCER INSTITUTE	Special Government Employee (SGE) Member
EMMONS, KAREN	11/03/2024	03/09/2030	PROFESSOR, DEPARTMENT OF SOCIAL AND BEHAVIORAL SCIENCE, HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH	Special Government Employee (SGE) Member
FELDER, TAMIKA	12/01/2024	03/09/2030	CHIEF VISIONARY, CERVIVOR, INC.	Special Government Employee (SGE) Member
FRIESE, CHRISTOPHER	01/30/2022	03/09/2026	ELIZABETH TONE HOSMER PROFESSOR OF NURSING, DIRECTOR, CENTER FOR IMPROVING PATIENT AND POPULATION SCIENCES, ASSOCIATE DIRECTOR FOR CANCER CONTROL AND POPULATION SCIENCES, UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER, UNIVERSITY OF MICHIGAN	Special Government Employee (SGE) Member

GORDON, JOHN	03/01/2023	12/31/2028	DIRECTOR FOR HEALTH SCIENCES, U.S. CONSUMER PRODUCT SAFETY COMMISSION	Ex Officio Member
GRABER, JOSEPH	11/12/2020	12/31/2025	SENIOR TECHNICAL ADVISOR, OFFICE OF BIOLOGICAL AND ENVIRONMENTAL RESEARCH, U.S. DEPARTMENT OF ENERGY	Ex Officio Member
GRANT, JULIE	09/24/2023	03/09/2028	GENERAL PARTNER, CANANN	Special Government Employee (SGE) Member
HAYES-DIXON, ANDREA	05/26/2020	03/09/2025	DEAN, HOWARD UNIVERSITY COLLEGE OF MEDICINE, VICE PRESIDENT OF CLINICAL AFFAIRS, CHAIR OF SURGERY, HOWARD UNIVERSITY HOSPITAL	Special Government Employee (SGE) Member
HEACOCK, MICHELLE	11/03/2023	12/31/2028	CHIEF, HAZARDOUS SUBSTANCES RESEARCH BRANCH, EXTRAMURAL RESEARCH AND TRAINING DIVISION, NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES, NATIONAL INSTITUTES OF HEALTH	Ex Officio Member
HEIMBERGER, AMY	01/30/2022	03/09/2026	JEAN MALNATI MILLER PROFESSOR OF BRAIN TUMOR RESEARCH, VICE CHAIR FOR RESEARCH, DEPARTMENT OF NEUROSURGERY, NORTHWESTERN UNIVERSITY, FEINBERG SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
KELLEY, MICHAEL	02/04/2008	12/31/2025	NATIONAL PROGRAM DIRECTOR FOR ONCOLOGY, U.S. DEPARTMENT OF VETERAN AFFAIRS	Ex Officio Member
NAVAS-ACIEN, ANA	08/27/2023	03/09/2028	PROFESSOR OF ENVIRONMENTAL HEALTH SCIENCES, DEPARTMENT OF ENVIRONMENTAL HEALTH SCIENCES, MAILMAN SCHOOL OF PUBLIC HEALTH, COLUMBIA UNIVERSITY	Special Government Employee (SGE) Member

NDUOM, EDJAH	11/03/2024	03/09/2030	DANIEL LOUIS BARRO ENDOWED CHAIR, PROFESSOR, DEPARTMENT OF NEUROSURGERY, EMORY UNIVERSITY SCHOOL OF MEDICINE, BRAIN TUMOR DISEASE LEADER, WINSHIP CANCER INSTITUTE	Special Government Employee (SGE) Member
PAZDUR, RICHARD	09/01/2002	12/31/2025	DIRECTOR, ONCOLOGY CENTER OF EXCELLENCE, U.S. FOOD AND DRUG ADMINISTRATION	Ex Officio Member
SHRIVER, CRAIG	08/22/2012	12/31/2028	DIRECTOR, JOHN P. MURTHA CANCER CENTER, U.S. DEPARTMENT OF DEFENSE	Ex Officio Member
SOUZA, KERRY	04/30/2013	12/31/2025	EPIDEMIOLOGIST, NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH PROFESSOR OF PEDIATRICS, HARVARD MEDICAL SCHOOL, TED WILLIAMS INVESTIGATOR, DANA-FARBER CANCER INSTITUTE, VICE CHAIR OF RESEARCH, PEDIATRIC ONCOLOGY,	Ex Officio Member Special Government Employee (SGE) Member
STEGMAIER, KIMBERLY	01/26/2024	03/09/2030	CO-DIRECTOR, PEDIATRIC HEMATOLOGIC MALIGNANCIES, PROGRAM, DANA-FARBER/CHILDREN'S HOSPITAL CANCER CENTER ASSISTANT PROFESSOR, DEPARTMENT OF INTERNAL MEDICINE,	 Special Government Employee (SGE) Member
TABUNG, FRED	08/27/2023	03/09/2028	COLLEGE OF MEDICINE AND COMPREHENSIVE CANCER CENTER, THE OHIO STATE UNIVERSITY BLOOMBERG DISTINGUISHED PROFESSOR OF CANCER BIOLOGY, E.V. MCCOLLUM CHAIR OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH, JOHNS HOPKINS UNIVERSITY	 Special Government Employee (SGE) Member
WEERARATNA, ASHANI	01/30/2022	03/09/2026		

WINKFIELD, KAREN	01/30/2022 03/09/2026	EXECUTIVE DIRECTOR	
		MEHARRY-VANDERBILT	
		ALLIANCE INGRAM	Special
		PROFESSOR OF CANCER	Government
		RESEARCH PROFESSOR	Employee
		OF RADIATION ONCOLOGY	(SGE)
		VANDERBILT UNIVERSITY	Member
		SCHOOL OF MEDICINE	

Number of Committee Members Listed: 26

Narrative Description

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. NCI works to fulfill that mission with the support of the National Cancer Advisory Board (NCAB), which is composed of both scientific and public members, and provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed \$50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). During the year, the NCAB was presented reports on various topics related to cancer research in general, and the operational aspects of the Institute's intramural and extramural programs. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing research programs.

What are the most significant program outcomes associated with this committee?

Checked if
Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input checked="" type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input checked="" type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Outcome Comments

The NCAB continues to be instrumental in monitoring the development and execution of the activities of the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. In 2024, NCI used its resources to support the best science and ensure continued advances with a focus on the eight goals of the National Cancer Plan which include the following: preventing cancer; detecting cancer early; developing effective treatments; eliminating inequities; delivering optimal care; engaging every person; maximizing data utility; and optimizing the workforce. There were also well-reasoned discussions regarding CDK4/6 Activity During the Cell Cycle by Live-Cell Imaging; Integrative Population-Based Characterization of Mosaic Chromosomal Alterations Uncovering Etiologic Insights for Hematologic Malignancies; Complexity of Genomic Aberrations in Human Breast Cancer for Precision Oncology; NCI Center for Cancer Genomics; NCI Virtual Clinical Trials Office Pilot Program; NCI's Support of Early Career Cancer Investigators; NCI's Childhood Cancer Data Initiative (CCDI); Artificial Intelligence (AI); the NCI Community Oncology Research Program (NCORP); and the National Clinical Trials Network (NCTN). NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittees on Experimental Therapeutics and Population Sciences, Epidemiology, and Disparities. Additionally, the Board deliberated and accepted the revised mission statement of the Ad Hoc Subcommittee on Experimental Therapeutics and approved the establishment of a Board of Scientific Advisors Ad Hoc Working Group in Support of Efforts to Enhance Community Cancer Research and Quality Care.

What are the cost savings associated with this committee?

Checked if Applies

None ☐

Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

282

Number of Recommendations Comments

In addition to some general recommendations, in FY 2024, some specific committee recommendations included the following: A motion to accept the report of the 29 November 2023 NCAB ad hoc Subcommittee on Experimental Therapeutics meeting was approved unanimously. A motion to accept the report of the 29 November 2023 NCAB Subcommittee on Cancer Centers meeting was approved unanimously. A motion to approve the NCI Annual Delegations of Authority was approved unanimously. A motion to accept the report of the 8 February 2024 NCAB ad hoc Subcommittee on Population Science, Epidemiology, and Disparities meeting was approved unanimously. A motion to accept the report of the 8 February 2024 NCAB ad hoc Subcommittee on Experimental Therapeutics meeting was approved unanimously. A motion to accept the report of the 8 February 2024 NCAB Subcommittee on Budget and Planning meeting was approved unanimously. A motion to concur on establishing a BSA ad hoc Working Group in Support of Efforts to Enhance Community Cancer Research and Quality Care was approved unanimously. A motion to accept the report of the 11 June 2024 NCAB Clinical Investigations Subcommittee meeting was approved unanimously. A motion to accept the report of the 11 June 2024 NCAB ad hoc Population Science, Epidemiology, and Disparities Subcommittee meeting was approved unanimously. A motion to accept the report of the 11 June 2024 NCAB ad hoc Experimental Therapeutics Subcommittee meeting was approved unanimously. A motion to accept the revised mission statement of the NCAB ad hoc Experimental Therapeutics Subcommittee was approved unanimously. A motion to accept the report of the 3 September 2024 NCAB ad hoc Subcommittee on

Population Science, Epidemiology, and Disparities meeting was approved unanimously. A motion to accept the report of the 3 September 2024 NCAB ad hoc Subcommittee on Experimental Therapeutics meeting was approved unanimously.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

0%

% of Recommendations Fully Implemented Comments

Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

0%

% of Recommendations Partially Implemented Comments

Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

Information is provided to the public at the open session of each Board meeting through reports and the Director's update. The public can view information related to the Board through the NCAB's official website.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input checked="" type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Action Comments

An action of approved or recommended for grants receiving review by this Board does not infer that the grant will be or has been funded. Research grant applications submitted to NIH must go through a two-step review process that includes the initial peer review for scientific and technical merit and a second step of review and approval by the National Advisory Council that includes program relevance. In addition, prior to an award or funding being made, NIH staff must conduct an administrative review for a number of other considerations. These include alignment with NIH's funding principles, review of the project budget, assessment of the applicant's management systems, determination of applicant eligibility, and compliance with public policy requirements. After all these steps, have been completed, NIH officials make funding decisions on individual grant applications. NCI used its resources to support the best science and ensure continued advances with a focus on the eight goals of the National Cancer Plan which include the following: preventing cancer; detecting cancer early; developing effective treatments; eliminating inequities; delivering optimal care; engaging every person; maximizing data utility; and optimizing the workforce. There were also well-reasoned discussions regarding CDK4/6 Activity During the Cell Cycle by Live-Cell Imaging; Integrative Population-Based Characterization of Mosaic Chromosomal Alterations Uncovering Etiologic Insights for Hematologic Malignancies; Complexity of Genomic Aberrations in Human Breast Cancer for Precision Oncology; NCI Center for Cancer Genomics; NCI Virtual Clinical Trials Office Pilot Program; NCI's Support of Early Career Cancer Investigators; NCI's Childhood Cancer Data Initiative (CCDI); Artificial Intelligence (AI); the NCI Community Oncology Research Program (NCORP); and the National Clinical Trials Network (NCTN). NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittees on Experimental Therapeutics and Population Sciences, Epidemiology, and Disparities.

Is the Committee engaged in the review of applications for grants?

Yes

What is the estimated **Number** of grants reviewed for approval

What is the estimated **Number** of grants recommended for 14,440
14,440

approval

What is the estimated **Dollar Value** of grants recommended for approval

\$5,669,337,484

Grant Review Comments

The number of grants reviewed/recommended and dollar value includes NCI grants and FDA SBIR grants.

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Access Comments

Information on the NCAB can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at <https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm>. Each NCI committee's charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint Presentations and reports is located here. Additionally, the public may view the NCAB meetings (both live and on demand) via the NIH Videocast at the following website: <http://videocast.nih.gov/>.